[Angiogenic growth factors in rheumatoid arthritis].
Yamashita
Akihisa
A
Department of Orthopedic Surgery, Graduate School of Medical Science, Kyushu University.
Yonemitsu
Yoshikazu
Y
D043925:Angiogenesis Inducing Agents; D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000209:etiology*; D002454:Cell Differentiation / Q000187:drug effects; D003864:Depression, Chemical; D016222:Fibroblast Growth Factor 2 / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006801:Humans; D018836:Inflammation Mediators; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D009389:Neovascularization, Pathologic; D010010:Osteoclasts / Q000166:cytology; D011506:Proteins / Q000627:therapeutic use; D017468:Receptors, Fibroblast Growth Factor / Q000235:genetics / Q000502:physiology; D029082:Sendai virus; D015398:Signal Transduction; D013583:Synovial Membrane / Q000098:blood supply / Q000166:cytology / Q000378:metabolism
D043925:Angiogenesis Inducing Agents; D000906:Antibodies; D018836:Inflammation Mediators; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D011506:Proteins; D017468:Receptors, Fibroblast Growth Factor; C485561:SPRY2 protein, human; D016222:Fibroblast Growth Factor 2